Literature DB >> 2587043

Extraocular muscle imbalance after scleral buckling surgery.

W E Smiddy1, D Loupe, R G Michels, C Enger, B M Glaser, S deBustros.   

Abstract

Pneumatic retinopexy is advocated to treat some retinal detachment cases, in part to avoid the complication of induced strabismus sometimes associated with scleral buckling procedures (SBPs). Prospective evaluation of postoperative muscle imbalance was performed in 76 eyes of 69 patients undergoing SBP. Measureable limitation of ductions occurred in 40 (73%) of the 55 eyes for which a full set of duction measurements could be obtained. Among 53 patients without previous retinal surgery in either eye, postoperative deviations were associated with encircling scleral buckles (P = 0.00003), but not with radial scleral buckles (P = 0.6). Significant strabismus occurred in 12 patients (23%), and three required surgery or prism therapy. Candidates for pneumatic retinopexy can usually be treated by a radial scleral buckling procedure, and therefore the risk of postoperative strabismus is low if this technique is selected.

Entities:  

Mesh:

Year:  1989        PMID: 2587043     DOI: 10.1016/s0161-6420(89)32701-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Strabismus following retinal detachment repair: a comparison between scleral buckling and vitrectomy procedures.

Authors:  S A Kasbekar; V Wong; J Young; T Stappler; J M Durnian
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

Review 2.  Iatrogenic diplopia [corrected].

Authors:  Julio González-Martín-Moro; Julio José González-López; Marco Sales-Sanz; Andrea Sales-Sanz; Javier González-Martín-Moro; Fernando Gómez-Sanz; Mar González-Manrique; Belén Pilo-de-la-Fuente; Roberto García-Leal
Journal:  Int Ophthalmol       Date:  2014-03-07       Impact factor: 2.031

3.  Pneumatic retinopexy with drainage of subretinal fluid.

Authors:  K Gündüz; I Günalp
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.